OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Morris on the Investigation of the Role of ctDNA in Stage II CRC

January 30th 2023

Van K. Morris, MD, discusses the evaluation of circulating tumor as a predictive biomarker for the use of adjuvant chemotherapy in patients with low-risk, stage II colon cancer.

Dr. Strickland on the Diagnosis of ESCC

January 30th 2023

Stephen A. Strickland, MD, MSCI, discusses a step-by-step approach for the diagnosis and workup of esophageal squamous cell carcinoma.

Dr. de Marinis on the PERLA Trial in Metastatic NSCLC

January 30th 2023

Filippo de Marinis, MD, discusses the goal of the phase 2 PERLA trial in metastatic nonsquamous non–small cell lung cancer, as well as significant results from a primary analysis of this study.

Dr. Phillips on the FDA Approval of Pirtobrutinib in MCL

January 27th 2023

Tycel Phillips, MD, discusses the significance of the FDA approval of pirtobrutinib in mantle cell lymphoma.

Dr. Schulte on the PRECISION 1 Trial of Nab-Sirolimus in TSC1/2-Mutated Solid Tumors

January 27th 2023

Brian Schulte, MD, discusses the ongoing phase 2 PRECISION 1 basket trial evaluating the use of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring TSC1/2 mutations.

Dr. Goodman on the Use of SBRT in Locally Advanced Pancreatic Cancer

January 27th 2023

Karyn A. Goodman, MD, MS, discusses key toxicity and efficacy data supporting the use of stereotactic body radiation therapy in locally advanced pancreatic cancer.

Dr. Hubbard on the Use of the PolyPEPI1018 Vaccine Plus Chemotherapy in Metastatic CRC

January 27th 2023

Joleen M. Hubbard, MD, discusses key survival data from the phase 1b study of the PolyPEPI1018 vaccine and the impact of these findings on continued investigations of this vaccine in metastatic colorectal cancer.

Dr. Palta on the Clinical Implications of the NRG/RTOG 1112 Trial in HCC

January 26th 2023

Manisha Palta, MD, discusses the clinical implications of the phase 3 NRG/RTOG 1112 trial in patients with locally advanced hepatocellular carcinoma.

Dr. Halmos on the Safety and Efficacy of Lurbinectedin in Second-line SCLC

January 26th 2023

Balazs Halmos, MD, discusses the safety and efficacy of lurbinectedin in the second-line setting for patients with small cell lung cancer.

Dr. George on Long-Term Data on Total Neoadjuvant Therapy in Rectal Cancer

January 26th 2023

Thomas J. George, MD, FACP, discusses long-term data from the phase 2 NRG-GI002 trial of total neoadjuvant therapy in locally advanced rectal cancer.

Dr. Pant on the RAGNAR Trial of Erdafitinib in Biliary Tract Cancer

January 26th 2023

Shubham Pant, MD, discusses the rationale, trial design, and key efficacy and safety data from an expansion cohort of the phase 2 RAGNAR trial in biliary tract cancers.

Dr. Rotroff on Biomarkers Associated With the Risk of Peripheral Neuropathy in Breast Cancer

January 25th 2023

Daniel Rotroff, PhD, discusses the investigation of biomarkers that could help identify patients with breast cancer who are at risk for developing chemotherapy-induced peripheral neuropathy.

Dr. Hecht on the Symptoms and Diagnosis of ESCC

January 25th 2023

J. Randolph (Randy) Hecht, MD, discusses the common symptoms of esophageal squamous cell carcinoma.

Dr. Chmielowski on the Potential Role of RP1 in Melanoma after Anti–PD-1 Failure

January 25th 2023

Bartosz Chmielowski, MD, discusses the potential role of vusolimogene oderparepvec in the treatment of patients with melanoma who failed prior treatment with an anti–PD-1 therapy.

Dr. Daver on the Use of ADCs in BPDCN

January 25th 2023

Naval Daver, MD, discusses the use of antibody-drug conjugates (ADC) in the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.

Dr. Pishvaian on the Implications of the RATIONALE-306 Trial in ESCC

January 25th 2023

Michael Jon Pishvaian, MD, PhD, discusses the clinical implications of the phase 3 RATIONALE 306 trial and the adverse effects associated with immunotherapy in patients with advanced esophageal squamous cell carcinoma.

Dr. Hunter on the Role of 18F-FES-PET Imaging in Triple-Positive Breast Cancer

January 25th 2023

Natasha B Hunter, MD, discusses the utility of 18F-Fluoroestradiol PET imaging for patients with estrogen receptor–positive and HER2-positive breast cancer.

Dr. Giralt on Long-Term Outcomes with HSCT in Multiple Myeloma

January 25th 2023

Sergio A. Giralt, MD, discusses long-term outcomes with hematopoietic stem cell transplant in multiple myeloma

Dr. Vicini on the Potential Utility of the DCISionRT Test in HER2+ DCIS of the Breast

January 25th 2023

Frank A. Vicini, MD, discusses the potential utility of using the DCISionRT test to determine treatment benefit in the phase 3 NRG-NSABP-B43 trial in HER2-positive ductal carcinoma in situ of the breast.

Dr. Stanton on Improving Responses to Immunotherapy in Early-Stage HR+ Breast Cancer

January 25th 2023

Sasha Stanton, MD, discusses efforts to improve the responses to immunotherapy regimens in early-stage hormone receptor–positive breast cancer.